IHL Stock Overview A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Incannex Healthcare Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Incannex Healthcare Historical stock prices Current Share Price AU$0.041 52 Week High AU$0.21 52 Week Low AU$0.041 Beta 2.09 1 Month Change -34.92% 3 Month Change -51.76% 1 Year Change -82.17% 3 Year Change -71.72% 5 Year Change 127.78% Change since IPO -52.87%
Recent News & Updates
Incannex Healthcare Inc., Annual General Meeting, Dec 11, 2024 Nov 02
Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer Oct 25
Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial Aug 06
Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X Jul 30 Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 04
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea May 31 See more updates
Incannex Healthcare Inc., Annual General Meeting, Dec 11, 2024 Nov 02
Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer Oct 25
Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial Aug 06
Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X Jul 30 Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 04
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea May 31
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder May 09
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N Feb 17
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis Jan 25
Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder Jan 19
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea Jan 17
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia Dec 22
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea Dec 06 Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity
Incannex Healthcare Limited Files Form 15 Nov 30
New minor risk - Financial data availability Aug 30
Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration Aug 25
Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States Aug 23
New minor risk - Market cap size Aug 04
Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis Jul 27
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea Jul 23
Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675 Jul 14
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea Jul 07
Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial Jun 17
Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin Jan 19 Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X Dec 08
Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea Nov 17
Less than half of directors are independent Nov 16
Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial Oct 13
Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury Oct 11
Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022 Oct 07
Full year 2022 earnings released: AU$0.012 loss per share (vs AU$0.012 loss in FY 2021) Sep 01
Less than half of directors are independent Aug 19
Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors Aug 17
Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders. Aug 06
Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A Aug 03
Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A Jul 21
Incannex Healthcare Limited Announces Board Changes Jun 29
Less than half of directors are independent Jun 10
Incannex Healthcare Limited Approves Election of George Anastassov as Director Jun 09
Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea Jun 03
Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea May 18 Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022. May 12
Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion May 10
First half 2022 earnings: Revenues and EPS in line with analyst expectations Mar 06
Incannex Healthcare (ASX:IHL) Is In A Good Position To Deliver On Growth Plans Feb 14
Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea Dec 20
Chairman of Medical Advisory Board exercised options to buy AU$7.1m worth of stock. Oct 08
Independent Non-Executive Chairman exercised options to buy AU$2.5m worth of stock. Sep 22
Chairman of Medical Advisory Board exercised options to buy AU$8.0m worth of stock. Sep 09
First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020) Aug 22
Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program Jul 23
Company Secretary Glenn Fowles has left the company Jul 15
Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results Mar 17
Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A Mar 12
Incannex Healthcare (ASX:IHL) Has Rewarded Shareholders With An Exceptional 774% Total Return On Their Investment Feb 28
Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results Feb 16
New 90-day high: AU$0.22 Feb 11
New 90-day high: AU$0.21 Feb 08
Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study Feb 04
Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021 Dec 17
Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study Dec 16
Incannex Healthcare Limited Receives Positive Results from Eurofins Dec 03
How Is Incannex Healthcare's (ASX:IHL) CEO Compensated? Dec 01
Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan) Nov 23
Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial Sep 24
Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer Sep 22
Full year earnings released - AU$0.0058 loss per share Aug 15 An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million. Aug 14
Shareholder Returns IHL AU Pharmaceuticals AU Market 7D 0% -4.9% -2.7% 1Y -82.2% -9.3% 6.5%
See full shareholder returns
Return vs Market: IHL underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility Is IHL's price volatile compared to industry and market? IHL volatility IHL Average Weekly Movement 14.7% Pharmaceuticals Industry Average Movement 10.3% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: IHL's share price has been volatile over the past 3 months.
Volatility Over Time: IHL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Show more Incannex Healthcare Inc. Fundamentals Summary How do Incannex Healthcare's earnings and revenue compare to its market cap? IHL fundamental statistics Market cap AU$65.07m Earnings (TTM ) -AU$19.98m Revenue (TTM ) AU$1.01m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IHL income statement (TTM ) Revenue AU$1.01m Cost of Revenue AU$0 Gross Profit AU$1.01m Other Expenses AU$20.99m Earnings -AU$19.98m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -0.013 Gross Margin 100.00% Net Profit Margin -1,970.61% Debt/Equity Ratio 0%
How did IHL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/12/01 13:29 End of Day Share Price 2023/11/17 00:00 Earnings 2023/06/30 Annual Earnings 2023/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Incannex Healthcare Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Arron Aatkar Edison Investment Research David Joseph Storms Stonegate Capital Partners, Inc.
Show 0 more analysts 
